| The evolving role of microsatellite instability in colorectal cancer: a review F Gelsomino, M Barbolini, A Spallanzani, G Pugliese, S Cascinu Cancer treatment reviews 51, 19-26, 2016 | 319 | 2016 |
| Targeting PI3K/AKT/mTOR pathway in breast cancer: From biology to clinical challenges K Cerma, F Piacentini, L Moscetti, M Barbolini, F Canino, A Tornincasa, ... Biomedicines 11 (1), 109, 2023 | 58 | 2023 |
| GD2 expression in breast cancer G Orsi, M Barbolini, G Ficarra, G Tazzioli, P Manni, T Petrachi, I Mastrolia, ... Oncotarget 8 (19), 31592, 2017 | 52 | 2017 |
| Predictive role of body composition parameters in operable breast cancer patients treated with neoadjuvant chemotherapy C Omarini, P Palumbo, A Pecchi, S Draisci, S Balduzzi, C Nasso, ... Cancer Management and Research, 9563-9569, 2019 | 26 | 2019 |
| Predictive factors for relapse in triple-negative breast cancer patients without pathological complete response after neoadjuvant chemotherapy A Toss, M Venturelli, M Civallero, C Piombino, F Domati, G Ficarra, ... Frontiers in Oncology 12, 1016295, 2022 | 13 | 2022 |
| Mutational profile of metastatic breast cancer tissue in patients treated with exemestane plus everolimus C Omarini, ME Filieri, S Bettelli, S Manfredini, S Kaleci, C Caprera, ... BioMed research international 2018 (1), 3756981, 2018 | 13 | 2018 |
| T-DM1 efficacy in trastuzumab-pertuzumab pre-treated HER2 positive metastatic breast cancer patients: a meta-analysis C Omarini, F Piacentini, I Sperduti, K Cerma, M Barbolini, F Canino, ... BMC cancer 22 (1), 623, 2022 | 9 | 2022 |
| Differential molecular pathways expression in HER2 positive early breast cancer according to hormone receptor status C Omarini, S Bettelli, C Caprera, S Manfredini, M Barbolini, L Moscetti, ... Journal of Cancer Research and Clinical Oncology 145, 821-828, 2019 | 9 | 2019 |
| Role of intrinsic subtype analysis with PAM50 in hormone receptors positive HER2 negative metastatic breast cancer: A systematic review F Canino, F Piacentini, C Omarini, A Toss, M Barbolini, P Vici, M Dominici, ... International Journal of Molecular Sciences 23 (13), 7079, 2022 | 8 | 2022 |
| Circulating and intracellular miRNAs as prognostic and predictive factors in HER2-positive early breast cancer treated with neoadjuvant chemotherapy: a review of the literature C Isca, F Piacentini, I Mastrolia, V Masciale, F Caggia, A Toss, ... Cancers 13 (19), 4894, 2021 | 8 | 2021 |
| Combined endocrine approaches vs endocrine therapy alone as first line treatment in elderly patients with hormone receptor-positive, HER2 negative, advanced breast cancer: to … C Omarini, F Piacentini, I Sperduti, M Barbolini, C Isca, A Toss, L Cortesi, ... BMC cancer 20, 1-10, 2020 | 8 | 2020 |
| Modulation of mutational landscape in HER2-positive breast cancer after neoadjuvant chemotherapy C Omarini, S Bettelli, S Manfredini, M Barbolini, C Isca, G Cortesi, ... Translational Oncology 13 (9), 100794, 2020 | 6 | 2020 |
| Henoch-schönlein Purpura (HSP) in a patient on Abemaciclib C Omarini, E Molinaro, M Barbolini, M Dominici, F Piacentini The Breast: official journal of the European Society of Mastology 52, 132, 2020 | 6 | 2020 |
| Pembrolizumab rechallenge in squamous non-small-cell lung cancer and HIV-positivity: a case report G Guaitoli, F Barbieri, M Barbolini, E Molinaro, KD Emidio, V Borghi, ... Immunotherapy 13 (4), 277-281, 2021 | 3 | 2021 |
| Real-world data and clinical implications of next-generation sequencing (NGS)-based analysis in metastatic breast cancer patients F Canino, A Tornincasa, S Bettelli, S Manfredini, M Barbolini, L Moscetti, ... International Journal of Molecular Sciences 25 (5), 2490, 2024 | 2 | 2024 |
| Endocrine-based targeted combination versus endocrine therapy alone as first-line treatment in elderly patients with hormone receptor-positive advanced breast cancer: Meta … C Omarini, F Piacentini, I Sperduti, M Barbolini, C Isca, C Nasso, A Toss, ... Journal of Clinical Oncology 37 (15_suppl), 1046-1046, 2019 | 2 | 2019 |
| Thromboembolism and Adjuvant Endocrine Therapy (AET) in Hormone Receptor-Positive Early Breast Cancer (EBC): Did Treatment Evolution Change Incidence of the Adverse Event? A … R D'Onofrio, I Sperduti, F Piacentini, M Barbolini, C Omarini, A Toss, ... Clinical Breast Cancer 23 (8), e534-e541, 2023 | 1 | 2023 |
| Clinical prognosticators in patients treated with CDK 4/6 inhibitors for hormone receptors positive advanced breast cancer C Isca, C Omarini, G Cortesi, M Luca, M Barbolini, M Dominici, ... JOURNAL OF CLINICAL TOXICOLOGY 10 (7), 1-6, 2020 | 1 | 2020 |
| A concise review of lenalidomide therapy for follicular lymphoma A Bari, R Marcheselli, M Barbolini, P Ferri, S Sacchi, S Pozzi Expert Opinion on Orphan Drugs 5 (3), 269-275, 2017 | 1 | 2017 |
| Update on Pulmonary Toxicity Induced by New Breast Cancer Treatments L Belluzzi, G Martinelli, B Medici, A Farina, E Martinelli, F Canino, ... Breast Cancer: Targets and Therapy, 53-66, 2025 | | 2025 |
